Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








The Moderna COVID-19 Vaccine’s Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events						Print
																Related Pages
										COVID-19 vaccine recommendations have been updated as of October 3, 2023 to add 2023-2024 updated Novavax COVID-19 vaccine. The content on this page will be updated to align with the new recommendations. Learn more.
On This PagePersons Aged 6 Months – 5 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse Events
Persons Aged 6 – 11 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse Events
Persons Aged 12 – 17 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse Events
Persons Aged ≥18 Years
Local Reactions
Systemic Reactions
Unsolicited Adverse Events
Serious Adverse EventsPersons Aged 6 Months – 5 Years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the older age group (ages 2 to 5 years) than the younger age group (ages 6-23 months)  (73.4% vs 54.4% after dose 2). Pain at the injection site was the most frequent and severe reported solicited local reaction among vaccine recipients. After dose 1, the older age group reported pain more frequently than the younger age group (61.4% vs 37.4%); a similar pattern was observed after dose 2 (71.4% vs 46.2%). Axillary (or groin) swelling or tenderness was the second most frequently reported local reaction. Axillary (or groin) swelling or tenderness was reported slightly more frequently in the younger age group than the older age group (9.3% vs 9.1% after dose 2). Injection site redness and swelling following either dose were reported less frequently. Redness and swelling were more common after dose 2. No grade 4 local reactions were reported. Overall, the median onset of local reactions in the vaccine group was 1 day after either dose, with a median duration of 2 days.Table 1. Local reactions in persons ages 6-23 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 1. Local reactions in persons ages 6-23 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N=1746
Placebo
N=582
mRNA-1273
N=1596
Placebo
N=526Rednessa, n (%)Any
150 (8.6)
24 (4.1)
215 (13.5)
20 (3.8)Severe
5 (0.3)
2 (0.3)
13 (0.8)
0Grade 4
0
0
0
0Swellinga  (hardness), n (%)Any
146 (8.4)
15 (2.6)
243 (15.2)
11 (2.1)Severe
5 (0.3)
0
14 (0.9)
0Grade 4
0
0
0
0Pain at the injection siteb, n (%)Any
652 (37.4)
175 (30.1)
738 (46.2)
135 (25.7)Severe
0
0
0
0Grade 4
0
0
0
0Axillary (or groin) swelling or tendernessb, n (%)Any
102 (5.9)
26 (4.5)
148 (9.3)
28 (5.3)Severe
0
0
0
0Grade 4
0
0
0
0Any local, n (%)Any
775 (44.4)
193 (33.2)
868 (54.4)
159 (30.2)Severe
9 (0.5)
2 (0.3)
22 (1.4)
0Grade 4
0
0
0
0
asevere: > 50 mm; Grade 4: necrosis or exfoliative dermatitis
bsevere: prevents daily activity; Grade 4: emergency room visit or hospitalizationTable 2. Local reactions in persons ages 2 – 5 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 2. Local reactions in persons ages 2 – 5 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N=2957
Placebo
N=970
mRNA-1273
N=2938
Placebo
N=959Rednessa, n (%)Any
164 (5.5)
14 (1.4)
259 (8.8)
15 (1.6)Grade 3 or above
12 (0.4)
3 (0.3)
12 (0.4)
0Swellinga (hardness), n (%)Any
134 (4.5)
17 (1.8)
240 (8.2)
11 (1.1)Grade 3 or above
10 (0.3)
2 (0.2)
13 (0.4)
0Pain at the injection siteb, n (%)Any
1813 (61.4)
382 (39.4)
2099 (71.4)
395 (41.2)Grade 3 or above
4 (0.1)
0
11 (0.4)
0Axillary (or groin) swelling or tendernessb, n (%)Any
205 (6.9)
56 (5.8)
267 (9.1)
31 (3.2)Grade 3 or above
0
0
1 (<0.1)
0Any local, n (%)Any
1874 (63.4)
407 (42.0)
2157 (73.4)
404 (42.1)Grade 3 or above
23 (0.8)
4 (0.4)
34 (1.2)
0
a Grade 3: > 100 mm; Grade 4: necrosis or exfoliative dermatitis
b Grade 3: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.Systemic Reactions
Solicited systemic adverse reactions were most common in the vaccine group than the placebo group and after dose 2 compared to dose 1. The most common solicited systemic adverse reactions after any dose were irritability/crying and fatigue for participants 6—36 months and 37 months—5 years, respectively.  The majority of systemic events were mild or moderate in severity, but there was a higher occurrence of grade 3 or higher reactions in the vaccine group. Grade 4 solicited systemic adverse reactions were reported for fever (placebo: 1/585, 0.2%; vaccine: 4/1758, 0.2%) in the 6-23 months age group. There were 13 fever events >40°C reported: 11 (0.4%) participants in the vaccine group and 2 (0.2%) in the placebo group among the 2 to 5-year-old-age group. Upon further review, 3 of the 13 fever events were incorrectly reported as grade 4, given that none of these 3 participants recorded any elevated temperature resulting in 10 confirmed grade 4 fevers: 8 (0.3%) in the mRNA-1273 group and 2 (0.2%) in the placebo group in the 2-5 age group. The majority of reactions occurred within the first 2 days after dose 1 and dose 2, persisting for a median of 3 and 2 days for the 6-23 months and 2-5 age groups respectively.Table 3. Systemic reactions in persons ages 6–23 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 3. Systemic reactions in persons ages 6–23 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1 6-23 Months
Dose 2 6-23 MonthsmRNA-1273
N=1746
Placebo
N=582
mRNA-1273
N=1596
Placebo
N=526Fevera, n (%)Any
191 (11.0)
49 (8.4)
232 (14.6)
44 (8.4)Grade 3 or higher
12 (0.7)
4 (0.7)
10 (0.6)
6 (1.1)Irritability/cryingb, n (%)Any
1175 (67.6)
361 (62.1)
1021 (64.3)
307 (58.5)Grade 3 or higher
24 (1.4)
6 (1.0)
25 (1.6)
5 (1.0)Sleepinessb, n (%)Any
645 (37.1)
217 (37.3)
558 (35.1)
175 (33.3)Grade 3 or higher
4 (0.2)
1 (0.2)
1 (<0.1)
1 (0.2)Loss of appetiteb, n (%)Any
524 (30.2)
152 (26.2)
510 (32.1)
132 (25.1)Grade 3 or higher
10 (0.6)
1 (0.2)
16 (1.0)
2 (0.4)Any systemic eventAny
1334 (76.4)
421 (72.3)
1174 (73.6)
350 (66.5)Grade 3 or higher
46 (2.6)
11 (1.9)
47 (2.9)
12 (2.3)
aGrade for fever: Any ≥38.0°C; grade 3=39.6-40.0°C; grade 4=> 40.0°C.
bGrade 3: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.Table 4. Systemic reactions in persons ages 24 – 36 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 4. Systemic reactions in persons ages 6–23 months, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1 24-36 months
Dose 2 24-36 monthsmRNA-1273
N=944
Placebo
N=320
mRNA-1273
N=963
Placebo
N=330Fevera, n (%)Any
106 (11.3)
25 (7.8)
182 (18.9)
35 (10.6)Grade 3 or higher
6 (0.6)
4 (1.3)
15 (1.6)
0Irritability/cryingb, n (%)Any
513 (54.5)
163 (51.1)
523 (54.3)
148 (44.8)Grade 3 or higher
12 (1.3)
6 (1.9)
10 (1.0)
2 (0.6)Sleepinessb, n (%)Any
285 (30.3)
92 (28.8)
347 (36.0)
89 (27.0)Grade 3 or higher
2 (0.2)
0
1 (0.1)
0Loss of appetiteb, n (%)Any
225 (23.9)
71 (22.3)
294 (30.5)
69 (20.9)Grade 3 or higher
7 (0.7)
1 (0.3)
8 (0.8)
0Any systemic eventAny
612 (65.0)
198 (61.9)
651 (67.6)
194 (58.8)Grade 3 or higher
21 (2.2)
10 (3.1)
31 (3.2)
2 (0.6)
aGrade for fever: grade 3=39.6-40.0°C; grade 4=> 40.0°C.
bGrade 3: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.Table 5. Systemic reactions in children ages 37 months – 5 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 5. Systemic reactions in children ages 37 months – 5 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N=2013
Placebo
N=650
mRNA-1273
N=1975
Placebo
N=629Fevera, n (%)Any
155 (7.7)
33 (5.1)
316 (16.0)
28 (4.5)Grade 3 or higher
24 (1.2)
5 (0.8)
62 (3.1)
2 (0.3)Headacheb, n (%)Any
232 (11.5)
78 (12.0)
310 (15.7)
51 (8.1)Grade 3 or higher
5 (0.2)
2 (0.3)
8 (0.4)
1 (0.2)Fatigueb, n (%)Any
807 (40.1)
236 (36.3)
956 (48.4)
185 (29.4)Grade 3 or higher
21 (1.0)
11 (1.7)
45 (2.3)
8 (1.3)New or worsening muscle painb, n (%)Any
200 (9.9)
60 (9.2)
310 (15.7)
47 (7.5)Grade 3 or higher
5 (0.2)
2 (0.3)
9 (0.5)
3 (0.5)New or worsening joint painb, n (%)Any
124 (6.2)
32 (4.9)
168 (8.5)
28 (4.5)Grade 3 or higher
2 (<0.1)
1 (0.2)
3 (0.2)
0Nausea/vomitingb, n (%)Any
137 (6.8)
50 (7.7)
194 (9.8)
30 (4.8)Grade 3 or higher
7 (0.3)
2 (0.3)
6 (0.3)
0Chillsb, n (%)Any
129 (6.4)
40 (6.2)
245 (12.4)
31 (4.9)Grade 3 or higher
1 (<0.1)
0
10 (1.0)
2 (0.3)Any systemic eventAny
983 (48.8)
290 (44.6)
1163 (58.9)
234 (37.2)Grade 3 or higher
48 (2.4)
15 (2.3)
104 (5.3)
11 (1.7)
aGrade for fever: grade 3=39-40.0°C; grade 4=> 40.0°C.
bGrade 3: prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.Unsolicited Adverse Events
The overall incidence of unsolicited adverse events up to 28 days after any dose were similar in the vaccine group (40.0%) and the placebo group (37.5%) for participants ages 2 – 5  years.  Adverse events in the vaccine group were similar in nature and incidence to those in the placebo group, with the exception of higher incidence of injection site erythema in the vaccine group compared to the placebo group (1.3% vs 0.2%) and COVID-19 in the placebo group compared to the vaccine group (5.5% vs 3.1%).
The overall incidence of unsolicited adverse events up to 28 days after any dose were similar in the vaccine group (49.3%) and the placebo group (48.2%) for participants ages 5—23 months.  In general, unsolicited adverse events experienced in the vaccine group were similar in nature and incidence to those in the placebo group. The following unsolicited adverse events were higher in the vaccine group compared with the placebo group by at least 1%: injection site lymphadenopathy (1.4% vs 0.2%); croup (1.3% vs 0.3%); diarrhea (3.2% vs 2.2%). The following were higher in the placebo group compared with the vaccine group by at least 1%: upper respiratory tract infection (12.2% vs 10.3%), COVID-19 (4.9% vs 3.5%), and otitis media (3.7% vs 2.6%).
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event were 0.5% in the vaccine group and 0.2% in the placebo group. In the younger age group, the most common serious adverse event occurring at higher rates in the vaccine group than the placebo group was febrile seizure (3 cases in vaccine group vs. 0 cases in placebo group). Other serious adverse events in the vaccine group included dehydration, metapneumovirus, foreign body respiratory tract infection, mastoiditis, bronchiolitis, pyrexia, rhinovirus, asthma, adenovirus infection, erythema multiforme, croup infectious, viral gastroenteritis, and 1 participant with Type 1 diabetes and diabetic ketoacidosis. In the placebo group there was 1 participant with bronchiolitis, rhinovirus and acute respiratory failure.
In the older age group, the most common serious adverse event occurring at higher rates in the vaccine group than the placebo group was pneumonias (2 cases in vaccine group vs. 0 cases in placebo group). Other serious adverse events in the vaccine group were bronchial hyperactivity, respiratory distress, adenovirus infection, seizure, rhinovirus infection (bronchiolitis due to rhinovirus), Epstein-Barr infection, urinary tract infection, and humerus fracture. In the placebo group serious adverse events, 1 participant experienced an abdominal wall abscess and 1 participant with rhinovirus infection and asthma.  Two serious adverse events in one participant were determined by the Food and Drug Administration (FDA) as potentially related to the vaccination. No specific safety concerns were identified among vaccine recipients aged 6 months–5 years.Top of PagePersons Aged 6 – 11 Years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. Local reactions in both groups were mostly grade mild or moderate; however, severe reactions were more frequent in the vaccine group than in the placebo group. There were no grade 4 local reactions reported. Pain at the injection site was the most frequent and severe reported solicited local reaction among vaccine recipients. Pain at the injection site was more common post Dose 2 (94.8%) than Dose 1 (93.1%). Injection site redness was the second most frequently reported local reaction. Injection site redness was more common after Dose 2 (18.7%) than Dose 1 (11.6%).  Axillary (or groin) swelling or tenderness and injection site swelling following either dose were reported less frequently and were more common after dose 2. There were no grade 4 local reactions reported. The majority of solicited local reactions occurred within the first 2 days after any dose, persisting for a median of 3.0 days.Table 6. Local reactions in persons aged 6-11 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 6. Local reactions in persons aged 6-11 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N=3004
Placebo
N=993
mRNA-1273
N=2988
Placebo
N=969Rednessa, n (%)Any
349 (11.6)
13 (1.3)
559 (18.7)
10 (1.0)Severe
16 (0.5)
1 (0.1)
33 (1.1)
1 (0.1)Grade 4
0
0
0
0Swellinga, n (%)Any
354 (11.8)
12 (1.2)
507 (17.0)
12 (1.2)Severe
19 (0.6)
1 (0.1)
20 (0.7)
0Grade 4
0
0
0
0Pain at the injection siteb, n (%)Any
2796 (93.1)
465 (46.8)
2832 (94.8)
480 (49.5)Severe
28 (0.9)
0
81 (2.7)
2 (0.2)Grade 4
0
0
0
0Axillary (or groin) swelling or tendernessb, n (%)Any
465 (15.5)
84 (8.5)
537 (18.0)
65 (6.7)Severe
3 (< 0.1)
1 (0.1)
3 (0.1)
2 (0.2)Grade 4
0
0
0
0Any local adverse reaction (n%)Any
2814 (93.7)
480 (48.3)
2849 (95.3)
490 (50.6)Severe
54 (1.8)
3 (0.3)
122 (4.1)
5 (0.5)Grade 4
0
0
0
0
a mild: 25-50 mm; moderate: 51-100 mm; severe: >100 mm; Grade 4=necrosis or exfoliative dermatitis.
b mild: no interference with activity; moderate: some interference with activity; severe: prevents daily activity; Grade 4: emergency room visit or hospitalizationSystemic Reactions
Systemic reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. The frequency and severity of systemic reactions was higher after dose 2 than dose 1 (78.1% vs 57.9%). Headache and fatigue were the most common systemic reactions. The majority of systemic reactions were mild or moderate in severity, after both doses. Fever was more common after the second dose (23.9%) compared to the first dose (3.3%). The majority of solicited systemic reactions occurred within the first 2 days after each, persisting for a median of 2 days.  One grade 4 fever was erroneously reported in the placebo group after dose 1. There were no other systemic grade 4 reactions reported. (Table 7)Table 7. Systemic reactions in persons aged 6–11 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 7. Local reactions in persons aged 6-11 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1 6-11 Years
Dose 2 6-11 YearsmRNA-1273
N=3004
Placebo
N=993
mRNA-1273
N=2988
Placebo
N=969Fever, n (%)Any
99 (3.3)
15 (1.5)
714 (23.9)
19 (2.0)Severe
17 (0.6)
2 (0.2)
113 (3.8)
2 (0.2)Grade 4
0
1* (0.1)
0
0Fatiguea, n (%)Any
1298 (43.2)
334 (33.6)
1925 (64.5)
335 (34.6)Severe
31 (1.0)
8 (0.8)
191 (6.4)
8 (0.8)Grade 4
0
0
0
0Headachea, n (%)Any
938 (31.2)
306 (30.8)
1622 (54.3)
275 (28.4)Severe
18 (0.6)
4 (0.4)
119 (4.0)
8 (0.8)Grade 4
0
0
0
0Chillsa, n (%)Any
309 (10.3)
67 (6.7)
904 (30.3)
74 (7.6)Severe
3 (< 0.1)
0
19 (0.6)
0Grade 4
0
0
0
0Nausea/vomitinga, n (%)Any
325 (10.8)
107 (10.8)
716 (24.0)
97 (10.0)Severe
5 (0.2)
0
19 (0.6)
0Grade 4
0
0
0
0New or worsening muscle paina, n (%)Any
438 (14.6)
96 (9.7)
843 (28.2)
105 (10.8)Severe
11 (0.4)
1 (0.1)
71 (2.4)
1 (0.1)Grade 4
0
0
0
0New or worsening joint paina, n (%)Any
260 (8.7)
75 (7.6)
482 (16.1)
84 (8.7)Severe
3 (< 0.1)
1 (0.1)
25 (0.8)
0Grade 4
0
0
0
0Any systemic eventAny
1740 (57.9)
518 (52.2)
2335 (78.1)
485 (50.1)Severe
53 (1.8)
12 (1.2)
364 (12.2)
14 (1.4)Grade 4
0
1 (0.1)
0
0
a Any: ≥38.0°C; Severe: 39°C to 40.0°C; Grade 4: >40.0°C
b Severe: prevents daily activity; Grade 4: emergency room visit or hospitalization
* Grade 4 event reported due to error in eDiary data entry, event was actually grade 0 (100.0°F).Unsolicited Adverse Events
Unsolicited adverse events were collected during the 28 days after each dose. A higher frequency of unsolicited adverse events was reported in the vaccine group compared to the placebo group (29.6% vs 25.1%). The main imbalances between the vaccine and placebo groups were general disorders and administration site conditions, consistent with the known reactogenicity profile of the vaccine. An increase in the incidence of injection site conditions were seen in the vaccine group (9.8%) compared to the placebo group (4.1%).  An imbalance of unsolicited adverse events in the skin and subcutaneous tissue disorders was also observed between the vaccine group (2.4%) and placebo group (1.0%). An increase in the incidence of the adverse event of COVID-19 was seen in the placebo group (2.2%) compared to the vaccine group (0.4%).
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event were 0.2% in the vaccine group and 0.2% in the placebo group. There were 7 SAEs among 6 participants in the vaccine group (appendicitis, cellulitis, cellulitis orbital, type 1 diabetes mellitus, appendicitis, pyelonephritis and urosepsis). There were 2 SAEs among 2 participants in the placebo group (affective disorder and COVID-19). No serious adverse events during the blinded randomized control trial were considered by the FDA as related to vaccine. In a review of additional SAEs accrued during open-label phase through data cutoff of February 21, 2022, one SAE of ileus in a participant with complex medical history was considered possibly related to vaccine.Top of PagePersons Aged 12 – 17 Years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Pain at the injection site was the most common and severe local reaction among vaccine recipients. Pain at the injection site was reported more frequently after dose 1 (93.1%) than after dose 2 (92.4%). Axillary swelling or tenderness was the second most frequently reported local reaction. Axillary swelling or tenderness was reported more frequently post dose 1 (23.2%) than dose 2 (21.0%). Injection site redness and swelling following either dose was reported slightly less frequently and was more common after dose 2 than dose 1. There were no grade 4 local reactions reported. The majority of solicited local adverse reactions in vaccine recipients occurred within the first 1 to 2 days after each dose and generally persisted for a median of 3 days (Table 8).Table 8. Local reactions in persons aged 12-17 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 8. Local reactions in persons aged 12-17 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N = 2,482
Placebo
N = 1,238
mRNA-1273
N = 2,478
Placebo
N = 1,220Rednessa, n (%)Any
334 (13.5)
8 (0.6)
484 (19.5)
11 (0.9)Severe
21 (0.8)
0
72 (2.9)
0Grade 4
0
0
0
0Swellinga, n (%)Any
403 (16.2)
12 (1.0)
509 (20.5)
12 (1.0)Severe
27 (1.1)
0
56 (2.3)
0Grade 4
0
0
0
0Pain at the injection siteb, n (%)Any
2,310 (93.1)
431 (34.8)
2,290 (92.4)
370 (30.3)Severe
133 (5.4)
1 (<0.1)
126 (5.1)
3 (0.2)Grade 4
0
0
0
0Axillary swelling or tendernessb, (n%)Any
578 (23.3)
101 (8.2)
519 (21.0)
61 (5.0)Severe
10 (0.4)
0
7 (0.3)
0Grade 4
0
0
0
0Any local adverse reaction, n (%)Any
2,339 (94.2)
455 (36.8)
2,314 (93.4)
398 (32.6)Severe
170 (6.8)
1 (<0.1)
220
3 (0.2)Grade 4
0
0
0
0
asevere: >10 cm; Grade 4: necrosis (redness and swelling categories) or exfoliative dermatitis (redness category only).
bsevere: any use of prescription pain reliever/prevents daily activity; Grade 4: emergency room visit or hospitalization for severe pain at the injection site.Systemic Reactions
Systemic reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. The frequency and severity of systemic reactions was higher after dose 2 than dose 1 (86.1% vs 68.5%). Headache and fatigue were the most common reactions. The majority of systemic reactions were mild or moderate in severity, after both doses. Fever was more common after the second dose (12.1%) compared to the first dose (2.5%). The majority of reactions occurred within the first 1 to 2 days after each dose and persisted for a median of 2 days. Grade 4 fever (>40.0°C) was reported by one vaccine recipient after dose 2 and one placebo recipient after dose 2. There was one report of grade 4 headache and one report of grade 4 nausea/vomiting, both after dose 2. No other systemic grade 4 reactions were reported. (Table 9)Table 9. Systemic reactions in persons aged 12-17 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Table 9. Systemic reactions in persons aged 12-17 years, Moderna mRNA-1273 COVID-19 vaccine and placebo
Dose 1
Dose 2mRNA-1273
N = 2,482
Placebo
N = 1,238
mRNA-1273
N = 2,478
Placebo
N = 1,220Fever, n (%)≥38.0°C
63 (2.5)
12 (1.0)
302 (12.2)
12 (1.0)38.0°C to 38.4°C
36 (1.5)
9 (0.7)
162 (6.5)
6 (0.5)38.5°C to 38.9°C
18 (0.7)
2 (0.2)
93 (3.8)
4 (0.3)39°C to 40.0°C
9 (0.4)
1 (<0.1)
46 (1.9)
1 (<0.1)>40.0°C
0
0
1 (<0.1)
1 (<0.1)Fatiguea, n (%)Any
1,188 (47.9)
453 (36.6)
1,679 (67.8)
353 (28.9)Severe
33 (1.3)
18 (1.5)
188 (7.6)
10 (0.8)Grade 4
0
0
0
0Headacheb, n (%)Any
1,106 (44.6)
477 (38.5)
1,739 (70.2)
370 (30.3)Severe
56 (2.3)
17 (1.4)
112 (4.5)
14 (1.1)Grade 4
0
0
1 (<0.1)
0Chillsc, n (%)Any
456 (18.4)
138 (11.1)
1,066 (43.0)
97 (8.0)Severe
4 (0.2)
1 (<0.1)
11 (0.4)
0Grade 4
0
0
0
0Nausea/vomitingd, n (%)Any
281 (11.3)
110 (8.9)
591 (23.9)
106 (8.7)Severe
2 (<0.1)
0
2 (<0.1)
0Grade 4
0
0
1 (<0.1)
0New or worsening muscle paina, n (%)Any
668 (26.9)
205 (16.6)
1154 (46.6)
153 (12.5)Severe
24 (1.0)
10 (0.8)
129 (5.2)
3 (0.2)Grade 4
0
0
0
0New or worsening joint paina, n (%)Any
371 (15.0)
143 (11.6)
716 (28.9)
113 (9.3)Severe
15 (0.6)
5 (0.4)
57 (2.3)
2 (0.2)Grade 4
0
0
0
0Any systemic eventAny
1,701 (68.5)
687 (55.5)
2,134 (86.1)
561 (46.0)Severe
108 (4.4)
36 (2.9)
340 (13.7)
25 (2.0)Grade 4
0
0
3 (0.1)
1 (<0.1)Use of antipyretic or pain medication, n (%)
748 (30.1)
118 (9.5)
1,242 (50.1)
108 (8.9)
a Severe: prevents daily activity; Grade 4: emergency room visit or hospitalization
b Severe: any use of prescription pain reliever or prevents daily activity; Grade 4: emergency room visit or hospitalization
c Severe: prevents daily activity and requires medical intervention; Grade 4: emergency room visit or hospitalization
d Severe: prevents daily activity, requires intravenous hydration; Grade 4: emergency room visit or hospitalization for hypotensive shock.Unsolicited Adverse Events
Unsolicited AEs were collected during the 28 days after each dose. A higher frequency of unsolicited adverse events after any dose was reported in the vaccine group (20.5%) compared to the placebo group (15.9%). The most commonly reported unsolicited adverse events after any vaccine dose were injection site lymphadenopathy (4.3%) and headache (2.2%). Imbalances in unsolicited adverse events in the vaccine group compared to the placebo group were observed and were primarily attributable to local injection site reactions including events of lymphadenopathy, erythema, induration, pain, pruritis, hypersensitivity, and urticaria. Incidence of lymphadenopathy was higher in the vaccine group (0.7%) than the placebo group (<0.1%). The majority of these events of lymphadenopathy occurred in the arm and neck region. An imbalance of unsolicited adverse events in the skin and subcutaneous tissue disorders was also observed between the vaccine group (1.1%) and placebo group (0.6%). The unsolicited adverse event of COVID-19 within 28 days of any dose was more frequently reported in the placebo group (1.0%) than the vaccine group (0.2%).
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event were 0.2% in the vaccine group and 0.2% in the placebo group. There were 9 SAEs among 6 vaccine recipients (appendicitis, diarrhea, vomiting, drug-induced liver injury, pectus excavatum, post-procedural fever, suicidal ideation [2], depression suicidal). There were 2 SAEs among 2 recipients (obstructive nephropathy and suicide attempt). No serious adverse events were considered by the FDA as related to vaccine.Top of PagePersons Aged ≥ 18 Years
Local Reactions
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the younger age group (aged 18 to 64 years) than the older age group (aged ≥65 years) (90.5% vs 83.9% after dose 2). Pain at the injection site was the most frequent and severe reported solicited local reaction among vaccine recipients. After dose 1, the younger age group reported pain more frequently than the older age group (86.9% vs 74.0%); a similar pattern was observed after dose 2 (90.1% vs 83.4%). Axillary swelling or tenderness was the second most frequently reported local reaction. Axillary swelling or tenderness was reported more frequently in the younger age group than the older age group (16.0% vs 8.4% after dose 2). Injection site redness and swelling following either dose were reported less frequently. Redness and swelling were slightly more common after dose 2. No grade 4 local reactions were reported. Overall, the median onset of local reactions in the vaccine group was 1 day after either dose, with a median duration between 2 and 3 days. (Table 10, Table 11)Table 10. Local reactions in persons aged 18-64 years, Moderna COVID-19 vaccine and placebo
Table 10. Local reactions in persons aged 18-64 years, Moderna COVID-19 vaccine and placebo
Dose 1
Dose 2Moderna Vaccine
N=11401
Placebo
N=**11404**
Moderna Vaccine
N=10357
Placebo
N=10317**Any Local, n (%)**Any
9960 (87.4)
2432 (21.3)
9371 (90.5)
2134 (20.7)Grade 3
452 (4.0)
39 (0.3)
766 (7.4)
41 (0.4)**Paina, n (%)**Any
9908 (86.9)
2179 (19.1)
9335 (90.1)
1942 (18.8)Grade 3
367 (3.2)
23 (0.2)
479 (4.6)
21 (0.2)**Rednessa, n (%)**Any
345 (3.0)
46 (0.4)
928 (9.0)
42 (0.4)Severe
34 (0.3)
11 (<0.1)
206 (2.0)
12 (0.1)**Swellingb, n (%)**Any
768 (6.7)
33 (0.3)
1309 (12.6)
35 (0.3)Grade 3
62 (0.5)
3 (<0.1)
176 (1.7)
4 (<0.1)**Axillary Swelling/Tendernessc, n (%)**Any
1322 (11.6)
567 (5.0)
1654 (16.0)
444 (4.3)Grade 3
36 (0.3)
13 (0.1)
45 (0.4)
10 (<0.1)
a Pain grade 3: any use of prescription pain reliever or prevented daily activity; grade 4: required emergency room visit or hospitalization.
b Swelling grade 3: >100mm/>10cm; grade 4: necrosis/exfoliative dermatitis.
c Axillary swelling or tenderness was collected as a solicited local adverse reaction (i.e., lymphadenopathy: localized axillary swelling or tenderness ipsilateral to the vaccination arm); grade 3: any use of prescription pain reliever or prevented daily activity; grade 4: required emergency room visit or hospitalization.
Note: No grade 4 local reactions were reported.Table 11. Local reactions in persons aged ≥65 years, Moderna COVID-19 vaccine and placebo
Table 11. Local reactions in persons aged ≥65 years, Moderna COVID-19 vaccine and placebo
Dose 1
Dose 2Moderna Vaccine**N=3762**
Placebo**N=3746**
Moderna Vaccine**N=3587**
Placebo**N=3549****Any Local, n (%)**Any
2805 (74.6)
566 (15.1)
3010 (83.9)
473 (13.3)Grade 3
77 (2.0)
39 (1.0)
212 (5.9)
29 (0.8)**Paina, n (%)**Any
2782 (74.0)
481(12.8)
2990 (83.4)
421 (11.9)Grade 3
50 (1.3)
32 (0.9)
96 (2.7)
17 (0.5)**Rednessa, n (%)**Any
86 (2.3)
19 (0.5)
265 (7.4)
13 (0.4)Grade 3
8 (0.2)
2 (<0.1)
75 (2.1)
3 (<0.1)**Swellingb, n (%)**Any
166 (4.4)
19 (0.5)
386 (10.8)
13 (0.4)Grade 3
20 (0.5)
3 (<0.1)
69 (1.9)
7 (0.2)**Axillary Swelling/Tendernessc, n (%)**Any
231 (6.1)
155 (4.1)
302 (8.4)
90 (2.5)Grade 3
12 (0.3)
14 (0.4)
21 (0.6)
8 (0.2)
a Pain grade 3: any use of prescription pain reliever or prevented daily activity; grade 4: required emergency room visit or hospitalization.
b Swelling grade 3: >100mm/>10cm; grade 4: necrosis/exfoliative dermatitis.
c Axillary swelling or tenderness was collected as a solicited local adverse reaction (i.e. lymphadenopathy: localized axillary swelling or tenderness ipsilateral to the vaccination arm); grade 3: any use of prescription pain reliever or prevented daily activity; grade 4: required emergency room visit or hospitalization.
Note: No grade 4 local reactions were reported.Systemic Reactions
Systemic reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. The frequency of systemic reactions was higher in the younger age group than the older age group (81.9% vs 71.9% after dose 2). Within each age group, the frequency and severity of systemic reactions was higher after dose 2 than dose 1. For both age groups, fatigue, headache and myalgia were the most common. The majority of systemic reactions were mild or moderate in severity, after both doses and in both age groups. Fever was more common after the second dose and in the younger group (17.6%) compared to the older group (10.2%). Among vaccine recipients, the median onset of systemic reactions was 1 to 2 days after either dose, with a median duration of 2 days. Grade 4 fever (>40.0°C) was reported by four vaccine recipients after dose 1 and 11 vaccine recipients after dose 2. There was one report of grade 4 fatigue and one report of grade 4 arthralgia, both in the younger age group after dose 1. In the older age group, there was one report of grade 4 nausea or vomiting after dose 2. No other systemic grade 4 reactions were reported. (Table 3, Table 4)Table 12. Systemic reactions in persons aged 18-64 years, Moderna COVID-19 vaccine and placebo
Table 12. Systemic reactions in persons aged 18-64 years, Moderna COVID-19 vaccine and placebo
Dose 1
Dose 2Moderna Vaccine**N=11405**
Placebo**N=11406**
Moderna Vaccine**N=10358**
Placebo**N=10320****Any systemic, n (%)**Any
6503 (57.0)
5063 (44.4)
8484 (81.9)
3967 (38.4)Grade 3
363 (3.2)
248 (2.2)
1801 (17.4)
215 (2.1)Grade 4
5 (<0.1)
4 (<0.1)
10 (<0.1)
2 (<0.1)**Fevera, n (%)**Any
105 (0.9)
39 (0.3)
1806 (17.4)
38 (0.4)Grade 3
10 (<0.1)
1 (<0.1)
168 (1.6)
1 (<0.1)Grade 4
4 (<0.1)
4 (<0.1)
10 (<0.1)
1 (<0.1)**Headacheb, n (%)**Any
4031(35.4)
3303 (29.0)
6500 (62.8)
2617 (25.4)Grade 3
219 (1.9)
162 (1.4)
515 (5.0)
124 (1.2)**Fatiguec, n (%)**Any
4384 (38.5)
3282 (28.8)
7002 (67.6)
2530 (24.5)Grade 3
120 (1.1)
83 (0.7)
1099 (10.6)
81 (0.8)Grade 4
1 (<0.1)
0 (0)
0 (0)
0 (0)**Myalgiac, n (%)**Any
2698 (23.7)
1626 (14.3)
6353 (61.3)
1312 (12.7)Grade 3
73 (0.6)
38 (0.3)
1032 (10.0)
39 (0.4)**Arthralgiac, n (%)**Any
1892 (16.6)
1327 (11.6)
4685 (45.2)
1087 (10.5)Grade 3
47 (0.4)
29 (0.3)
603 (5.8)
36 (0.3)Grade 4
1 (<0.1)
0 (0)
0 (0)
0 (0)**Nausea/Vomitingd, n (%)**Any
1069 (9.3)
908 (8.0)
2209 (21.3)
754 (7.3)Grade 3
6 (<0.1)
8 (<0.1)
8 (<0.1)
8 (<0.1)**Chillse, n (%)**Any
1051 (9.2)
730 (6.4)
5001 (48.3)
611 (5.9)Grade 3
17 (0.1)
8 (<0.1)
151 (1.5)
14 (0.1)
a Fever – Grade 3: ≥39.0 – ≤40.0°C or ≥102.1 – ≤104.0°F; Grade 4: >40.0°C or >104.0°Fb Headache – Grade 3: significant; any use of prescription pain reliever or prevented daily activity; Grade 4: required emergency room visit or hospitalization.c Fatigue, Myalgia, Arthralgia – Grade 3: significant; prevented daily activity; Grade 4: required emergency room visit or hospitalization.d Nausea/Vomiting – Grade 3: prevented daily activity, required outpatient intravenous hydration; Grade 4: required emergency room visit or hospitalization for hypotensive shock.e Chills – Grade 3: prevented daily activity and required medical intervention; Grade 4: required emergency room visit or hospitalization.Table 13. Systemic reactions in persons aged ≥65 years, Moderna COVID-19 vaccine and placebo
Table 13. Systemic reactions in persons aged ≥65 years, Moderna COVID-19 vaccine and placebo
Dose 1
Dose 2Moderna Vaccine**N=3761**
Placebo**N=3748**
Moderna Vaccine**N=3589**
Placebo**N=3549****Any systemic, n (%)**Any
1818 (48.3)
1335 (35.6)
2580 (71.9)
1102 (31.1)Grade 3
84 (2.2)
63 (1.7)
387 (10.8)
58 (1.6)Grade 4
0 (0)
0 (0)
2 (<0.1)
1 (<0.1)**Fevera, n (%)**Any
10 (0.3)
7 (0.2)
366 (10.2)
5 (0.1)Grade 3
1 (<0.1)
1 (<0.1)
18 (0.5)
0 (0)Grade 4
0 (0)
2 (<0.1)
1 (<0.1)
1 (<0.1)**Headacheb, n (%)**Any
921 (33.3)
443 (11.8)
1665 (46.4)
635 (17.9)Grade 3
30 (0.8)
34 (0.9)
107 (3.0)
32 (0.9)**Fatiguec, n (%)**Any
1251 (38.5)
851 (22.7)
2094 (58.4)
695 (19.6)Grade 3
120 (1.1)
23 (0.6)
248 (6.9)
20 (0.6)**Myalgiac, n (%)**Any
743 (19.8)
443 (11.8)
1683 (46.9)
385 (10.8)Grade 3
17 (0.5)
9 (0.3)
201 (5.6)
10 (0.3)**Arthralgiac, n (%)**Any
618 (16.4)
456 (12.2)
1252 (34.9)
381 (10.7)Grade 3
13 (0.3)
8 (0.2)
122 (3.4)
7 (0.2)**Nausea/Vomitingd, n (%)**Any
194 (5.2)
166 (4.4)
425 (11.8)
129 (3.6)Grade 3
4 (0.1)
4 (0.1)
10 (0.3)
3 (<0.1)Grade 4
0 (0)
0 (0)
1 (<0.1)
0 (0)**Chillse, n (%)**Any
202 (5.4)
148 (4.0)
1099 (30.6)
144 (4.1)Grade 3
7 (0.2)
6 (0.2)
27 (0.8)
2 (<0.1)
a Fever – Grade 3: ≥39.0 – ≤40.0°C or ≥102.1 – ≤104.0°F; Grade 4: >40.0°C or >104.0°Fb Headache – Grade 3: significant; any use of prescription pain reliever or prevented daily activity; Grade 4: requires emergency room visit or hospitalization.c Fatigue, Myalgia, Arthralgia – Grade 3: significant; prevented daily activity; Grade 4: required emergency room visit or hospitalization.d Nausea/Vomiting – Grade 3: prevented daily activity, required outpatient intravenous hydration; Grade 4: Requires emergency room visit or hospitalization for hypotensive shock.e Chills – Grade 3: prevented daily activity and required medical intervention; Grade 4: required emergency room visit or hospitalization.Unsolicited Adverse Events
A higher frequency of unsolicited adverse events was reported in the vaccine group compared to the placebo group and was primarily attributed to local and systemic reactogenicity following vaccination. Reports of lymphadenopathy were imbalanced with 1.1 % of persons in the vaccine group and 0.6% in the placebo group reporting such events; lymphadenopathy is plausibly related to the vaccine. Lymphadenopathy occurred in the arm and neck region and was reported within 2 to 4 days after vaccination. The median duration of lymphadenopathy was 1 to 2 days. Bell’s palsy was reported by three vaccine recipients and one placebo recipient. One case of Bell’s palsy in the vaccine group was considered a serious adverse event. Currently available information is insufficient to determine a causal relationship with the vaccine.
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability or incapacity. The proportions of participants who reported at least one serious adverse event were 1% in the vaccine group and 1% in the placebo group. The most common serious adverse events occurring at higher rates in the vaccine group than the placebo group were myocardial infarction (5 cases in vaccine group vs. 3 cases in placebo group), cholecystitis (3 vs. 0), and nephrolithiasis (3 vs. 0). Three serious adverse events were considered by the U.S. Food and Drug Administration (FDA) as possibly related to vaccine: the one report of intractable nausea/vomiting and two reports of facial swelling in persons who had a previous history of cosmetic filler injections. The possibility that the vaccine contributed to the serious adverse event reports of rheumatoid arthritis (n=1), peripheral edema/dyspnea with exertion (n=1), and autonomic dysfunction (n=1) cannot be excluded.
Data source: FDA briefing documentTop of Page
							
					
							Last Reviewed:  June 21, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue